Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease
| العنوان: | Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease |
|---|---|
| المؤلفون: | Simon Bertram Reuter, Julia S. Johansen, Jens Kastrup, Naja Dam Mygind, Marina Harutyunyan |
| المصدر: | Biomarkers in Medicine. 8:977-988 |
| بيانات النشر: | Future Medicine Ltd, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Myocardial ischemia, medicine.medical_treatment, Clinical Biochemistry, Myocardial Ischemia, Ischemia, Inflammation, Coronary Artery Disease, Revascularization, Coronary artery disease, Young Adult, Adipokines, Risk Factors, Lectins, Internal medicine, Drug Discovery, Myocardial Revascularization, medicine, Humans, In patient, Chitinase-3-Like Protein 1, Growth Substances, Aged, Aged, 80 and over, business.industry, Biochemistry (medical), Percutaneous coronary intervention, Middle Aged, Prognosis, medicine.disease, Survival Rate, Case-Control Studies, Disease Progression, Cardiology, Biomarker (medicine), Female, medicine.symptom, business, Biomarkers, Follow-Up Studies |
| الوصف: | Aim: The aim was to investigate the inflammatory biomarker YKL-40 as a monitor of myocardial ischemia in patients with coronary artery disease (CAD). Methods: A total of 311 patients with stable CAD were included. Blood samples were taken at baseline, the day after coronary angiography and/or after percutaneous coronary intervention and after 6 months. Results: A total of 148 (48%) patients were revascularized and 163 patients underwent only coronary angiography. In the entire population, serum YKL-40 increased significantly from baseline to 6 months (p = 0.05). This tendency was seen in nonrevascularized patients (p = 0.06), but not in revascularized patients (p = 0.46). Serum YKL-40 increased approximately 25% the day after the invasive procedure (p < 0.001) and then decreased significantly to nearly baseline after 6 months (p = 0.002). Conclusion: Serum YKL-40 is a potential promising biomarker of disease progression but not of myocardial ischemia in patients with stable CAD. |
| تدمد: | 1752-0371 1752-0363 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aacd393df5a809f46c2403fd382c1da5Test https://doi.org/10.2217/bmm.14.20Test |
| رقم الانضمام: | edsair.doi.dedup.....aacd393df5a809f46c2403fd382c1da5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17520371 17520363 |
|---|